Literature DB >> 17234972

MicroRNAs play an essential role in the development of cardiac hypertrophy.

Danish Sayed1, Chull Hong, Ieng-Yi Chen, Jacqueline Lypowy, Maha Abdellatif.   

Abstract

MicroRNAs are naturally existing, small, noncoding RNA molecules that downregulate posttranscriptional gene expression. Their expression pattern and function in the heart remain unknown. Here we report an array of microRNAs that are differentially and temporally regulated during cardiac hypertrophy. Significantly, the muscle-specific microRNA-1 (miR-1) was singularly downregulated as early as day 1 (0.56+/-0.036), persisting through day 7 (0.29+/-0.14), after aortic constriction-induced hypertrophy in a mouse model. Overexpression experiments showed that miR-1 inhibited its in silico-predicted, growth-related targets, including Ras GTPase-activating protein (RasGAP), cyclin-dependent kinase 9 (Cdk9), fibronectin, and Ras homolog enriched in brain (Rheb), in addition to protein synthesis and cell size. Thus, we propose that microRNAs play an essential regulatory role in the development of cardiac hypertrophy, wherein downregulation of miR-1 is necessary for the relief of growth-related target genes from its repressive influence and induction of hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17234972     DOI: 10.1161/01.RES.0000257913.42552.23

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  326 in total

1.  Systems analysis reveals down-regulation of a network of pro-survival miRNAs drives the apoptotic response in dilated cardiomyopathy.

Authors:  Ruth Isserlin; Daniele Merico; Dingyan Wang; Dajana Vuckovic; Nicolas Bousette; Anthony O Gramolini; Gary D Bader; Andrew Emili
Journal:  Mol Biosyst       Date:  2014-10-31

2.  Acute targeting of general transcription factor IIB restricts cardiac hypertrophy via selective inhibition of gene transcription.

Authors:  Danish Sayed; Zhi Yang; Minzhen He; Jessica M Pfleger; Maha Abdellatif
Journal:  Circ Heart Fail       Date:  2014-11-14       Impact factor: 8.790

3.  Environmental chemical exposures and human epigenetics.

Authors:  Lifang Hou; Xiao Zhang; Dong Wang; Andrea Baccarelli
Journal:  Int J Epidemiol       Date:  2011-12-13       Impact factor: 7.196

Review 4.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

Review 5.  microRNAs in heart disease: putative novel therapeutic targets?

Authors:  Gianluigi Condorelli; Michael V G Latronico; Gerald W Dorn
Journal:  Eur Heart J       Date:  2010-01-29       Impact factor: 29.983

Review 6.  MicroRNAs challenge the status quo of therapeutic targeting.

Authors:  Danish Sayed; Shweta Rane; Maha Abdellatif
Journal:  J Cardiovasc Transl Res       Date:  2008-09-09       Impact factor: 4.132

7.  Trisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteins.

Authors:  Terry S Elton; Sarah E Sansom; Mickey M Martin
Journal:  RNA Biol       Date:  2010-09-01       Impact factor: 4.652

8.  Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support.

Authors:  Scot J Matkovich; Derek J Van Booven; Keith A Youker; Guillermo Torre-Amione; Abhinav Diwan; William H Eschenbacher; Lisa E Dorn; Mark A Watson; Kenneth B Margulies; Gerald W Dorn
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

9.  MicroRNA-regulated pathways associated with endometriosis.

Authors:  E Maria C Ohlsson Teague; Kylie H Van der Hoek; Mark B Van der Hoek; Naomi Perry; Prabhath Wagaarachchi; Sarah A Robertson; Cristin G Print; Louise M Hull
Journal:  Mol Endocrinol       Date:  2008-12-12

Review 10.  MicroRNAs in myocardial ischemia: identifying new targets and tools for treating heart disease. New frontiers for miR-medicine.

Authors:  V Sala; S Bergerone; S Gatti; S Gallo; A Ponzetto; C Ponzetto; T Crepaldi
Journal:  Cell Mol Life Sci       Date:  2013-11-12       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.